| Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. | |
| | |
MedLine Citation:
|
PMID: 17042913 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. Serotonin (5-HT), as a type of mitogen for smooth muscle cells, plays an important role in the development of pulmonary hypertension. It is known that selective serotonin re-uptake inhibitors (SSRI) inhibit 5-HT internalization. Therefore, the aim of the present study was to investigate the protective effect and mechanism of the SSRI sertraline against pulmonary hypertension. 2. Monocrotaline (MCT)-induced chronic 'inflammatory' pulmonary hypertension in Wistar rats was established. Pulmonary haemodynamic measurement and lung tissue morphological investigations were undertaken. Serotonin transporter (SERT) mRNA was assayed by reverse transcription-polymerase chain reaction (RT-PCR). 3. The results showed that pulmonary artery pressure (PAP) was significantly increased by MCT treatment from 12.6 +/- 2.1 to 20.1 +/- 3.4 mmHg (P < 0.01 vs control) and sertraline attenuated the MCT-induced increase in PAP from 20.1 +/- 3.4 to 16.4 +/- 1.8 mmHg (P < 0.05 vs MCT). The right ventricular index was increased in the MCT-treated group from 0.32 +/- 0.04 to 0.51 +/- 0.09 (P < 0.01 vs control) and was reduced to 0.42 +/- 0.04 by sertraline (P < 0.05 vs MCT). The degree of muscularization of the pulmonary artery in the MCT-treated group was significantly higher than control (P < 0.01) and was decreased by sertraline (P < 0.01 vs MCT). The RT-PCR assay showed that MCT increased SERT mRNA expression from 0.86 +/- 0.08 to 0.99 +/- 0.06 (P < 0.05 vs control), which was attenuated by sertraline (0.82 +/- 0.09; P < 0.05 vs MCT). 4. In conclusion, the SSRI sertraline protects against MCT-induced pulmonary hypertension by decreasing PAP, right ventricular index and pulmonary artery remodelling, which may be related to a reduction in SERT mRNA. |
| | |
Authors:
|
Xue-Qin Li; Yang Hong; Yun Wang; Xin-Hua Zhang; Huai-Liang Wang |
Related Documents
:
|
20411253 - Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pedi... 23329973 - Occipital artery arising from the anterior aspect of the internal carotid artery identi... 16052843 - Massive pulmonary embolism in a woman with leiomyomatous uterus causing pelvic deep ven... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental pharmacology & physiology Volume: 33 ISSN: 0305-1870 ISO Abbreviation: Clin. Exp. Pharmacol. Physiol. Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-10-17 Completed Date: 2007-02-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0425076 Medline TA: Clin Exp Pharmacol Physiol Country: Australia |
Other Details:
|
Languages: eng Pagination: 1047-51 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, China Medical University, Shenyang, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Gene Expression Regulation Hypertension, Pulmonary / chemically induced*, prevention & control* Male Monocrotaline / toxicity* RNA, Messenger Rats Rats, Wistar Serotonin Plasma Membrane Transport Proteins / metabolism Serotonin Uptake Inhibitors / therapeutic use* Sertraline / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/RNA, Messenger; 0/Serotonin Plasma Membrane Transport Proteins; 0/Serotonin Uptake Inhibitors; 0/Slc6a4 protein, rat; 315-22-0/Monocrotaline; 79617-96-2/Sertraline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminas...
Next Document: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume ...